Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Viva Biotech Holdings (VBIZF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Viva Biotech Holdings $0.26, price $0.19, upside +35.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? No
- Add to watchlist
VB
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Viva Biotech Holdings
VBIZF · USSpeculativeUpside exists, but weak quality makes the signal speculative.
✓Fair value $0.2600 · Undervalued (+35.6%)
!Quality 37/100
!Weak Growth (revenue 5y +19.3 %/yr)
✓Solidly profitable · 12.7% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 44/100
!Evidence only low, so the estimate is less certain
Watch Viva Biotech Holdings for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0050 – $1.50 · fair‑value band $0.1500 – $0.3300 · the $0.1917 price screens below the $0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
Show more
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Stock analysis
Viva Biotech Holdings (VBIZF) currently trades at $0.1917, while our model-based Fair Value estimate is $0.2600, implying the stock looks roughly 26.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.3800 per share, and 18 of the 24 models we run sit above the $0.1917 price.
Bear case: the Economic Profit group reads lowest at $0.1100, and 6 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1500 (bear) to $0.3300 (bull), the price of $0.1917 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Viva Biotech Holdings reported revenue of 1.7B CNY in FY2025 versus 2.1B CNY in FY2021, a compound −5.4%/yr. Reported net income was 214M CNY in FY2025, compounding −7.1%/yr from FY2021.
Key figures
Market cap $448M · P/E ratio 19.2 · P/S ratio 2.44 · EPS (TTM) $0.0100 · Dividend yield 5.8% · Net margin 12.7% · Return on equity 6.9% · Return on assets (EBIT) 3.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 36%, VBIZF screens cheaper than that median.
Fair Value models
Bear $0.1500
Fair Value $0.2600
Bull $0.3300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0076 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.1100
$0.1700
$0.2800
76
Growth DCF
$0.1100
$0.1700
$0.2500
75
EPV
$0.1000
$0.1100
$0.1200
74
All 24 models by family
DCF Models
FCF DCF
$0.1100
$0.1700
$0.2800
76
Owner Earnings
$0.2700
$0.4600
$0.7700
72
5Y Revenue Exit
$0.1400
$0.2400
$0.3800
69
5Y EBITDA Exit
$0.2300
$0.4500
$0.7400
70
5Y P/E Exit
$0.2100
$0.3900
$0.6200
67
10Y Revenue Exit
$0.1200
$0.2100
$0.3500
63
10Y EBITDA Exit
$0.1800
$0.3500
$0.6300
63
10Y P/E Exit
$0.1700
$0.3100
$0.5400
59
Earnings-Based
Graham-Dodd
$0.1000
$0.6200
$0.8700
61
Lynch FV
$0.1800
$0.2500
$0.3300
59
PEG = 1.0
$0.1800
$0.2500
$0.3300
55
EPV
$0.1000
$0.1100
$0.1200
74
Multiples
P/E Multiple
$0.2500
$0.3400
$0.4200
63
P/S Multiple
$0.2000
$0.2600
$0.3300
58
P/B Multiple
$0.2000
$0.2600
$0.3300
55
EV/EBIT
$0.2000
$0.2600
$0.3200
66
EV/EBITDA
$0.3300
$0.4200
$0.5200
67
EV/Revenue
$0.1500
$0.2000
$0.2600
54
Asset-Based
NCAV (Graham)
$0.1400
$0.1900
$0.2900
53
Growth DCF
Growth DCF
$0.1100
$0.1700
$0.2500
75
Rev-Margin DCF
$0.1400
$0.2300
$0.3700
69
Economic Profit
Residual Income
$0.2000
$0.1900
$0.2000
68
ROIC Compounder
$0.1000
$0.1100
$0.1200
70
Growth Earnings
Growth-Adj P/E
$0.2600
$0.3800
$0.4900
65
Notify me when VBIZF reaches fair value
Put VBIZF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
37/100
Of which business quality 37 · Market factors (momentum, volatility) 12
Profitability
29
Margins and returns on capital today
Quality Growth
33
Are margins and returns improving?
Cashflow
32
Earnings quality: real cash, not paper profit
Fin. Strength
48
Balance sheet, leverage, solvency risk
Investment
85
Disciplined investing over empire-building
Low Volatility
17
Calm price path (market factor)
Momentum
0
Price trend over the last 3–12 months (market factor)
52W Momentum
27
Distance to the 52-week high (market factor)
Net Issuance
5
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.8%
Dividend (yield on the price)5.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10.8% vs 18.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 11%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +28.8% a year for the price.
Watch VBIZF, get fair value alerts →
Compare Viva Biotech Holdings with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Viva Biotech Holdings (VBIZF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2600 versus the last price from Sep 25, 2026 of $0.1917, about +36% upside (undervalued).
What is the fair value of VBIZF?
Our model-based fair value for Viva Biotech Holdings is $0.2600 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.1917.
What is the quality score of VBIZF?
Viva Biotech Holdings has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Viva Biotech Holdings (VBIZF)?
Our model-based price target is the fair value of $0.2600 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.1500, optimistic scenario $0.3300. It is a calculation from audited fundamentals, not an analyst target.
What is the Viva Biotech Holdings stock forecast for 2026?
Our models put fair value at $0.2600, about +36% upside versus the last price from Sep 25, 2026 of $0.1917 (undervalued). Cautious scenario $0.1500, optimistic scenario $0.3300. The calculation is refreshed regularly with new filings.
What is the revenue of Viva Biotech Holdings (VBIZF)?
Viva Biotech Holdings reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Sep 24, 2026).
Does Viva Biotech Holdings pay a dividend?
Viva Biotech Holdings currently shows a dividend yield of about 5.80% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Viva Biotech Holdings (VBIZF)?
For today's price to be fair in a discounted-cash-flow model, Viva Biotech Holdings would have to grow free cash flow by +30.9 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of VBIZF use?
Our models discount Viva Biotech Holdings at 13.9 %: a base by market capitalisation (micro), damped by beta 1.36, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Viva Biotech Holdings that is +30.9 % per year a year over ten years, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Viva Biotech Holdings (VBIZF) delivered so far?
Over the past 5 years revenue at Viva Biotech Holdings grew +19.3 % a year. The price currently implies +30.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Viva Biotech Holdings (VBIZF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Viva Biotech Holdings (+30.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Viva Biotech Holdings (VBIZF)?
The free-cash-flow yield on the price is 2.93 %: that much free cash flow Viva Biotech Holdings produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Viva Biotech Holdings (VBIZF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Viva Biotech Holdings it is $0.2600 per share (as of Sep 24, 2026), against a price of $0.1917. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Viva Biotech Holdings stock overvalued or undervalued in 2026?
As of Sep 24, 2026, VBIZF trades below its calculated fair value: price $0.1917, fair value $0.2600, a gap of about +36% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VBIZF?
No. The price is what the market pays today ($0.1917); the fair value is what the company's own numbers justify ($0.2600). For Viva Biotech Holdings the two are $0.0683 per share apart. That gap is exactly why we show both numbers side by side.
How much is Viva Biotech Holdings worth?
The market values Viva Biotech Holdings at about $448M (market capitalisation, as of Sep 24, 2026). Per share that is $0.1917; our models calculate a fair value of $0.2600 per share.
What do the bullish and bearish scenarios say about VBIZF?
Our models span a range for Viva Biotech Holdings: cautious scenario $0.1500, base $0.2600, optimistic $0.3300 per share (as of Sep 24, 2026, price $0.1917). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VBIZF?
Viva Biotech Holdings trades at a price-to-earnings ratio of 19.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.2600 is built from several models across several years.
How solid is the balance sheet of Viva Biotech Holdings (VBIZF)?
Balance-sheet figures for Viva Biotech Holdings (as of Sep 24, 2026): return on equity 6.9%, debt of 0.18 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is VBIZF from its 52-week high?
Viva Biotech Holdings trades at $0.1917, about 55% below its 52-week high of $0.4294 and 42% above the low of $0.1349 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2600 is for.
Which stocks are comparable to Viva Biotech Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Viva Biotech Holdings stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1917, calculated fair value $0.2600 (+36%), Quality Score 37/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VBIZF calculated?
We run Viva Biotech Holdings through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Viva Biotech Holdings currently trades 26 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Viva Biotech Holdings (VBIZF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.1917. Our model-based fair value is $0.2600, about +36% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Viva Biotech Holdings right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1500 to $0.3300) leaves room in how you read the outcome.
Key figures of Viva Biotech Holdings
How large is the market capitalisation of Viva Biotech Holdings (VBIZF)?
The market capitalisation of Viva Biotech Holdings is $448M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Viva Biotech Holdings (VBIZF)?
The price-to-sales ratio of Viva Biotech Holdings is 2.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Viva Biotech Holdings (VBIZF)?
Earnings per share at Viva Biotech Holdings are $0.0100 (price ÷ EPS = P/E 19.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Viva Biotech Holdings (VBIZF)?
The dividend yield of Viva Biotech Holdings is 5.8% (payout 111%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Viva Biotech Holdings (VBIZF)?
The net margin of Viva Biotech Holdings is 12.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Viva Biotech Holdings (VBIZF)?
The return on equity (ROE) of Viva Biotech Holdings is 6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Viva Biotech Holdings (VBIZF)?
On an EBIT basis the return on assets of Viva Biotech Holdings is 3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Viva Biotech Holdings (VBIZF)?
The operating margin of Viva Biotech Holdings is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Viva Biotech Holdings (VBIZF)?
Revenue at Viva Biotech Holdings is growing −10.7% versus a year earlier (3y avg −10.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Viva Biotech Holdings (VBIZF)?
Earnings per share at Viva Biotech Holdings are growing +117% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Viva Biotech Holdings (VBIZF) carry?
The net debt of Viva Biotech Holdings is 222M CNY (fiscal year 2025, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Viva Biotech Holdings in the live analysis
One click puts Viva Biotech Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.